SCHEMBL20205888

SCHEMBL20205888

CN1CCCC1C(=O)NC1(Cc2ccccc2)CCN(S)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.49
ADRB2 P07550 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.39
CYP2C19 P33261 1/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
MMP1 P03956 1/20 0.38
MMP7 P09237 1/20 0.38
MMP8 P22894 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
DPP4 P27487 1/20 0.38
HTR6 P50406 2/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158532 0.92 RET (0.49) RETADRB2ALDH1A1HTTCYP3A4
SCHEMBL20147376 0.88 RET (0.47) RETADRB2ALDH1A1HTTCYP3A4
SCHEMBL20068813 0.88 RET (0.46) RETADRB2ALDH1A1HTTCYP3A4
SCHEMBL20069617 0.84 RET (0.53) RETALDH1A1HTTCYP3A4CYP2D6
SCHEMBL22856984 0.76 RET (0.54) RETALDH1A1HTTCYP3A4CYP2D6
SCHEMBL20137706 0.76 RET (0.52) RETALDH1A1HTTPKMFKBP1A
SCHEMBL20137709 0.76 RET (0.52) RETALDH1A1HTTPKMFKBP1A
SCHEMBL20147901 0.75 RET (0.44) RETADRB2ALDH1A1HTTMMP8
SCHEMBL24820758 0.74 CYP3A4 (0.64) ALDH1A1CYP3A4CYP2C9PKMCYP2C19
SCHEMBL10144672 0.74 CYP3A4 (0.64) ALDH1A1CYP3A4CYP2C9PKMCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885ADRB2 3956/4885ALDH1A1 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.